Skip to main content
Premium Trial:

Request an Annual Quote

Decode Reports Decreased Q3 Revenues

NEW YORK, Nov. 14 - Decode Genetics today reported decreased revenue for the third quarter of 2002.

 

The company said its total revenue was $9 million in the third quarter which ended September 30, compared to $9.7 million in the same quarter of 2001.

 

Decode reported a net loss of $85.7 million, or $1.61 per share, in the third quarter 2002 compared to a net loss of $8.9 million, or $.20 per share, in the year-ago period. The company said the increased loss reflected in part a substantial one-time milestone revenue received in the year-ago period. Additionally, in the current third quarter Decode recorded impairment, employee termination benefits, and other charges of $64.8 million as a result of the acquisition of MediChem Life Sciences in March.

 

R&D spending increased to $23.5 million compared to $16.8 million in the same period a year ago.

 

Decode also reported $104.9 million in cash and cash equivalents, including $6 million in restricted cash, at the end of September 2002.

 

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.